Search

Home > News & Events > Current News

Current News

Current SATVI news

6 March 2019 Latest Research: A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates
Tue, 05 Mar 2019 - 20:15

SATVI researchers Miguel Rodo, Professor Tom Scriba, Drs. Virginie Rozot, Elisa Nemes and Profesor Mark Hatherill have published a article titled: "A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates" appearing in the PLoS Pathogens journal.

4 March 2019: 2018 Annual Report Now Available
Tue, 05 Mar 2019 - 18:45

The South African Tuberculosis Vaccine Initiative 2018 Annual Report is now available. 

19 January 2019 Research Published: Toll-like receptor chaperone HSP90B1 and the immune response to Mycobacteria
Mon, 04 Feb 2019 - 15:00

SATVI Authors Professors Mark Hatherill, Tom Scriba, Dr Munyaradzi Musvosvi, Humphrey Mulenga, Ashley Veldsman have co-authored a research paper titled "Toll-like receptor chaperone HSP90B1 and the immune response to Mycobacteria" appearing in the PLos One Journal.

17 January 2019 Research Published: Batf2 differentially regulates tissue immunopathology in Type 1 and 2 diseases
Mon, 04 Feb 2019 - 14:30

Professor Tom Scriba and Dr Adam Penn-Nicholson have co-authored a research publication titled: "Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases" appearing in the Mucosal Immunology Journal.

11 December 2018 Research Published Building capacity for advances in TB research
Tue, 11 Dec 2018 - 14:30

Professor Mark Hatherill has co-authored a journal article titled "Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting" appearing in the Tuberculosis (Edinb) Journal.

6 December 2018 Research Published: Metabolite changes in blood predict the onset of TB
Fri, 07 Dec 2018 - 14:00

Professor Tom Scriba has co-authored a paper titled: “Metabolite changes in blood predict the onset of tuberculosis” in the  Nature Journal.

1 December 2018 Research Published: Safety and Immunogenicity of early Bacillus Calmette-Guerin (BCG) vaccination in infants who are preterm and/or have low birth weights:
Tue, 04 Dec 2018 - 14:00

Prof Mark Hatherill has co-authored a journal article titled: "Safety and Immunogenicity of early Bacillus Calmette-Guerin (BCG) vaccination in infants who are preterm and/or have low birth weights: A systematic review and meta-analysis" appearing in the Journal of American Medical Association (JAMA).

15 November 2018 Research: Commentary WHO Preferred Product Preferences for TB Vaccines
Thu, 15 Nov 2018 - 11:30

SATVI Director Professor Mark Hatherill has co-authored a commentary titled "WHO preferred product characteristics for new vaccines against tuberculosis" appearing in The Lancet journal.

13 November 2018 Research: Can we predict tuberculosis cure? What tools are available?
Tue, 13 Nov 2018 - 12:45

Associate Professor Tom Scriba has co authored a paper titled "Can we predict tuberculosis cure? What tools are available?" appearing in the European Respiratory Journal of the European Respiratory Society.

LIVE PRESS CONFERENCE: Union World Conference on Lung Health : M72 Vaccine study primary results presented
Sun, 28 Oct 2018 - 09:30

Watch the press conference during which the primary results from the M72/AS01E candidate vaccine were announced during the Union World Conference on Lung Health. Professor Mark Hatherill, SATVI Director spoke on behalf of SATVI.

23 October 2018 SATVI at the Union Conference on Lung Health
Tue, 23 Oct 2018 - 12:00

View the full list of SATVI speakers at the The Union World Conference on Lung Health held from 24 to 27 October 2018.

25 September 2018 Research Published: Candidate tuberculosis (TB) vaccine can prevent active pulmonary TB in HIV-negative adults in phase II study
Tue, 25 Sep 2018 - 17:45

The New England Journal of Medicine has just published the primary results of an ongoing phase IIb clinical trial testing the candidate tuberculosis vaccine M72/AS01E which demonstrates that the M72/AS01E vaccine significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults who were already infected with latent TB at the time of vaccination.

Pages